AAO LIVE: Researchers target risk factors for development of rhegmatogenous retinal detachmentsOctober 3rd 2022
In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, William Kearney and Dan Gong, MD, discussed how patients with a unilateral retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.
Pooled Phase 3 data reports safety, efficacy, reduced treatment burden with faricimab compared with aflibercept for the treatment of nAMDOctober 2nd 2022
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
AAO LIVE: Study finds retinal detachment rates unaffected by early treatment with intravitreal antivirus or vitrectomy in patients with acute retinal necrosisOctober 2nd 2022
In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.
Center-involved DME resolves faster with faricimab than afliberceptOctober 2nd 2022
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
AAO: Janssen announces late-breaking data from a pair of gene therapy programsOctober 2nd 2022
In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Faricimab: YOSEMITE, RHINE treat-and-extend data illustrate favorable personalized treatment dynamics for the treatment of DMESeptember 30th 2022
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
EP. 2: EyeCon 2022: Location, location, location and bring the familySeptember 28th 2022
The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.
Alimera announces agreement with Jaeb Center for Health Research for studySeptember 23rd 2022
Fluocinolone acetonide intravitreal implant or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy
EP. 1: EyeCon 2022: Nothing is better than in-person conferencesSeptember 21st 2022
Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.
Iveric Bio announces positive topline data from avacincaptad pegol GATHER2 Phase 3 clinical trial in geographic atrophySeptember 6th 2022
GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. With this data in hand, Iveric Bio is working to submit a New Drug Application for Zimura to the FDA by the end of the first quarter of next year.
Oculis presents of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edemaSeptember 6th 2022
According to a presentation by the company at the 22nd EURETINA World Congress in Hamburg, Germany, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
EURETINA LIVE: Research focuses on retinal issues following COVID-19 infectionSeptember 4th 2022
A study detailed at the 22nd EURETINA Congress in Hamburg, Germany, documented a spectrum of manifestations following COVID-19 infections in an otherwise immunocompetent patient presenting at a tertiary care center.
EURETINA 2022: LIGHT study offers first analysis of gene therapy for RPE65 inherited retinal dystrophiesSeptember 3rd 2022
At the 22nd EURETINA World Congress in Hamburg, Germany,Isabelle Audo, MD, reported that voretigene neparvovec used to treat patients with a RPE65-related inherited retinal dystrophy, showed good safety and efficacy at the 1-year time point of the LIGHT Study.